Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -130.20% is 77% above its 5-year average of -560.04%, near the high end of its 5-year range (-16279.79%–776.38%).
97.52% above its 12-month average of -5253.01%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): 76.04%.
OPERATING MARGIN
-130.20%
OPERATING MARGIN AVG TTM
-5253.01%
OPERATING MARGIN AVG 3Y
-3270.79%
OPERATING MARGIN AVG 5Y
-560.04%
OPERATING MARGIN AVG 10Y
-404.87%
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+97.52%
CURRENT VS 3Y AVG
+96.02%
CURRENT VS 5Y AVG
+76.75%
CURRENT VS 10Y AVG
+67.84%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
MeiraGTx Holdings plc
Market Cap
$989.20M
Operating Margin
-130.20%
TTM Avg
-5253.01%
3Y Avg
-3270.79%
5Y Avg
-560.04%
Market Cap
$991.32M
Operating Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$987.04M
Operating Margin
-33.86%
TTM Avg
-38.38%
3Y Avg
-66.13%
5Y Avg
-173.51%
Market Cap
$986.98M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$996.22M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$979.94M
Operating Margin
2.47%
TTM Avg
-2.95%
3Y Avg
4.03%
5Y Avg
7.25%
Market Cap
$1.01B
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-59.79%
Market Cap
$964.49M
Operating Margin
-1149.52%
TTM Avg
-2324.93%
3Y Avg
-1162.47%
5Y Avg
-1162.47%
Market Cap
$1.02B
Operating Margin
-377.11%
TTM Avg
-200.94%
3Y Avg
-143.24%
5Y Avg
-174.04%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | $989.20M | -130.20% | -5253.01% | -3270.79% | -560.04% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $991.32M | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $987.04M | -33.86% | -38.38% | -66.13% | -173.51% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $986.98M | 0.00% | 0.00% | 0.00% | 0.00% |
| Vor Biopharma Inc. (VOR)vs › | $996.22M | 0.00% | 0.00% | 0.00% | 0.00% |
| Pacira BioSciences, Inc. (PCRX)vs › | $979.94M | 2.47% | -2.95% | 4.03% | 7.25% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | 0.00% | 0.00% | 0.00% | -59.79% |
| Aktis Oncology, Inc. (AKTS)vs › | $964.49M | -1149.52% | -2324.93% | -1162.47% | -1162.47% |
| Immatics N.V. (IMTX)vs › | $1.02B | -377.11% | -200.94% | -143.24% | -174.04% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.02B | -8.99% | -4.92% | -23.48% | -24.49% |
Gross Margin
97.2%
Operating Margin
-130.2%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | 76.04% |
| 2026-03-31 | -13930.72% |
| 2025-12-31 | 35.13% |
| 2025-09-30 | -11231.95% |
| 2025-06-30 | -1213.57% |
| 2025-03-31 | -2159.71% |
| 2024-12-31 | -147.22% |
| 2024-09-30 | -367.01% |
| 2024-06-30 | -16279.79% |
| 2024-03-31 | -6710.47% |
| 2023-12-31 | -2144.80% |
| 2023-09-30 | -642.01% |
| 2023-06-30 | -813.14% |
| 2023-03-31 | -952.61% |
| 2022-12-31 | 776.38% |
| 2022-09-30 | -473.59% |
| 2022-06-30 | -220.82% |
| 2022-03-31 | -510.10% |
| 2021-12-31 | -38.61% |
| 2021-09-30 | -324.63% |
| 2021-06-30 | -400.37% |
| 2021-03-31 | -479.48% |
| 2020-12-31 | -348.97% |
| 2020-09-30 | -165.55% |
| 2020-06-30 | -1019.60% |
| 2020-03-31 | -372.48% |
| 2019-12-31 | -78.40% |
| 2019-09-30 | -304.44% |
| 2019-06-30 | -1071.18% |
| 2019-03-31 | -2635.90% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
